Search
Replimune's Chairman discusses FDA's polarizing decision to not approve the company's melanoma treatment after a new review. He says they have filed a FOIA request to learn more about FDA's process
Philip Astley-Sparke describes the timeline of development of this oncolytic immunotherapy, his impression of FDA's review process and decisions around it, and the status of where the treatment stands today.
Apr 22
After receiving a CRL for its RP1 oncolytic immunotherapy yesterday, the CEO of Replimune walks us through the program's timeline and history, and what this might mean for its future
CEO Sushil Patel walks us through the decisions behind the design of the IGNYTE phase 1/2 study and the ongoing IGNYTE-3 study, he gives...
Jul 23, 2025
Replimune's CEO discusses last week's PD-1 refractory melanoma data and the company's plans to file for accelerated approval
Sushil Patel describes Replimune's ASCO and follow-on data from last week in the context of PD-1 response rates and competitor data from...
Jun 10, 2024
Modality profile: Oncolytic Immunotherapies at #ASCO23
Replimune Founder and Head of R&D Robert Coffin describes the oncolytic immunotherapy approach to cancer research.
Jun 3, 2023
.png){kind=logo}
